The Molecular Profiling Institute Launches Mammostrat(TM) A Novel, Molecular Targeted, Prognostic Test For Breast Cancer Patients

The Molecular Profiling Institute,
Inc. (Molecular Profiling) announced that they are now providing
Mammostrat, a new molecular-targeted breast prognostic test, to breast
cancer patients, nationwide. The Mammostrat prognostic test utilizes five
immunohistochemical (IHC) biomarkers to classify patients into high,
moderate, or low-risk categories for disease recurrence.


Robert Penny, M.D., Ph.D., the Chairman and CEO of the Molecular
Profiling Institute stated, "Mammostrat will benefit the care of breast
cancer patients nationwide by allowing their cancer to be quickly analyzed
for prognosis by a direct light-microscopic evaluation of the cancer cells
by a pathologist. This new test, which is performed on tissue preserved
according to standard practice, streamlines the process for patients while
providing the accuracy of direct visualization."



The test was developed by Applied Genomics, Inc. who rigorously
translated recent genomic insights in cancer into a novel
immunohistochemistry test. Mammostrat test results have been validated
using over a thousand patient samples in North America from
clinics/organizations such as the Cleveland Clinic Foundation and the
National Surgical Adjuvant Breast and Bowel Project -- generating results
with clear cut conclusions from multiple independent studies supporting the
prognostic value of the test.



"We are excited to have partnered with the Molecular Profiling
Institute, says Doug Ross, MD, PhD, Chief Scientific Officer of Applied
Genomics. "Their expertise in advanced genomic and proteomic testing will
provide a rigorous reference lab-based introduction of the test and broad
reach in order to offer quality testing to patients nationwide."



Because Mammostrat uses traditional immunohistochemistry technology,
the test is expected to be significantly less expensive than existing
molecular-based, prognostic tests for breast cancer and is typically
covered by insurance. Todd Maney, Ph.D., Vice President of New Product
Development, MPI, stated, "Mammostrat's cost-effective, molecular-targeted
analysis enables MPI to provide the test at a significant discount compared
to our competitors. Moreover, test results will be available quickly -- an
average of seven business days -- versus two weeks for alternative,
comparable tests."



Physicians may order the Mammostrat test direct from the Molecular
Profiling Institute or through their distribution partner AmeriPath by
visiting molecularprofiling.



About the Molecular Profiling Institute, Inc. -- Molecular Profiling is
a CLIA-certified specialty reference laboratory that helps patients,
worldwide, by applying the discoveries of the Human Genome Project to
personalized medicine. Molecular Profiling provides cutting-edge testing
facilities, products, and resources for genomic and proteomic profiling and
treatment of complex diseases, and pharmaceutical services to identify
populations that may respond to targeted therapies. Molecular Profiling
leverages strategic relationships with a number of organizations, including
AmeriPath, Inc., the International Genomics Consortium (IGC), and the
Translational Genomics Research Institute (TGen). Molecular Profiling's Web
site address is molecularprofiling.



About Applied Genomics -- Applied Genomics, Inc. develops targeted
diagnostics to improve treatment for cancer patients. Translating insights
from genomic analyses of cancer, AGI creates antibody-based diagnostic
tests for classifying cancer facilitating rational patient care decisions
and improving quality of life for all patients. AGI has ongoing product
development programs in breast, lung, ovarian, head and neck, and colon
cancer. Additional company information is available at:
applied-genomics.


The Molecular Profiling Institute, Inc.

molecularprofiling